KALAMAZOO, Michigan, USA, March 2, 2023 /PRNewswire/ -- Stryker (NYSE:SYK) announced the launch of its CD NXT System, the latest innovation in the company's power tools. This patented technology provides real-time depth measurement as the surgeon drills, allowing for fast, accurate, consistent digital depth measurement across various procedures.
CD NXT streamlines instrumentation and surgical steps, offering an accurate and reproducible measurement while removing errors commonly associated with a manual depth gauge. The system works independently of the implant system, allowing broad use across the market.
"We continuously listen to the needs and pain points of our customers. We discovered the need for a more accurate and dependable depth measurement tool through research. CD NXT fills that gap through a revolutionary technology allowing the power tool to communicate information back to the surgeon, enabling real-time decision-making," said Bill Scott, vice president and general manager of Stryker's Orthopaedic Instruments business.
CD NXT features include:
For more information, including videos, please visit Stryker's CD NXT System product page at https://www.stryker.com//us/en/orthopaedic-instruments/products/cd-nxt.html
About Stryker
Stryker is one of the world's leading medical technology companies and, together with its customers, is driven to make healthcare better. The company offers innovative products and services in Medical and Surgical, Neurotechnology, Orthopaedics and Spine that help improve patient and healthcare outcomes. Alongside its customers around the world, Stryker impacts more than 130 million patients annually. More information is available at www.stryker.com.
Media contact
Beth Sizemore
Sr. Director, Strategic Communications
Instruments
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$361.20 |
Daily Change: | -5.91 -1.61 |
Daily Volume: | 125,562 |
Market Cap: | US$137.700B |
November 19, 2024 November 14, 2024 October 29, 2024 September 20, 2024 September 17, 2024 |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREImmix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB